With so much online fraud where will pharma money go?

KEY TAKEAWAY: According to Fierce Pharma “Outcome Health went into crisis communications mode after a Wall Street Journal article last week said the fast-growing pharma services company had misled its advertisers. Within hours, the company posted a letter to clients—on its website and social media—outlining in detail how it was addressing the problem”.  Just pile on the fraud! Continue reading

Celgene proves pharma greed is alive and well

KEY TAKEAWAY: A report found that 27 percent of cancer survivors or close relatives of a cancer patient said they’d skipped doctor visits or taken other steps to reduce health costs.  Yet, according to Fierce Pharma  “defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the range that many Big Pharma peers have pledged to avoid”.  Continue reading

Pharma gives the middle finger to patients

KEY TAKEAWAY:Gilead, which recently acquired Kite Pharma in an all cash deal, said the list price for Yescarta, which is to be administered just once to each patient, would be $373,000. The cost is supposed to make us feel good because the price is well below that of the first drug in this new class such as $475,000 for Novartis’s  Kymriah.

Continue reading

Pharma not wholly to blame for opioid epidemic

According to the Atlantic “opioid abuse is rampant in states like Ohio, where paramedics are increasingly spending time responding to overdoses and where coroners’ offices are running out of room to store bodies. In 2012, there were 793 million doses of opioids prescribed in the state, enough to supply every man, woman, and child, with 68 pills each”.  But is pharma really to blame? Continue reading